Is PT-141 (Bremelanotide) Legal in Virginia?
HealthRX.com
Vyleesi is legal in Virginia with a prescription
Key numbers
- 1.75 mgVyleesi single-dose autoinjector strength for premenopausal women with acquired HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Share of Vyleesi users with nausea in pooled phase 3 trials (placebo: 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 dosesMaximum Vyleesi doses per month the label says is not recommended to exceedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 18%Share of Vyleesi users who stopped due to adverse reactions in phase 3 (placebo: 2%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Drug name / Bremelanotide, approved as Vyleesi; 'PT-141' is the common research name
- Approval / NDA 210557, June 21, 2019 [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Dose and route / 1.75 mg subcutaneous autoinjector, as needed, at least 45 minutes before activity (per the label) [1]
- Regulatory status / Prescription-only; no boxed warning and no REMS [1][2]
- Compounded PT-141 / Not FDA-approved; not reviewed for safety, effectiveness or quality [4]
- Virginia rules / Drug Control Act: prescriptions, compounding, pharmacy permits [3]
What federal approval does and does not cover
FDA approved bremelanotide under NDA 210557 on June 21, 2019 [2]. It is sold as Vyleesi, a prefilled autoinjector. The label gives the dose as 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].
The approval is narrow. Vyleesi is indicated for premenopausal women with acquired, generalized HSDD: low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1]. Vyleesi carries no boxed warning and no risk evaluation and mitigation strategy [1][2].
Compounded and research-use PT-141 is a different product
Products sold as PT-141 by peptide vendors and compounding pharmacies are not Vyleesi, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [4]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks, in the version of that page dated 04/22/2026 [5], and it is not one of the six peptides addressed by HHS's October 2026 draft enforcement-discretion policy [6]. Absence from those lists is not an FDA approval.
What Virginia's Drug Control Act covers
Virginia regulates drugs through Chapter 34 of Title 54.1, the Drug Control Act [3]. Its sections include requirements for prescriptions (§ 54.1-3408.01), a pharmacist's authority to compound under certain conditions (§ 54.1-3410.2), a section titled "Prohibition on refusing to fill prescription from telemedicine provider" (§ 54.1-3420.3), a permit to conduct a pharmacy (§ 54.1-3434) and a permit to act as an outsourcing facility (§ 54.1-3434.05) [3]. These are the general state provisions for prescriptions and pharmacies.
Key label safety points
The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [1]. Each dose transiently raises blood pressure and lowers heart rate, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose and returning to baseline usually within 12 hours [1]. In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi users versus 1.3% on placebo, and flushing in 20.3% versus 0.3%; 18% of Vyleesi users discontinued because of adverse reactions versus 2% on placebo [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Is PT-141 (Bremelanotide) legal in Virginia?
Do I need a prescription for PT-141 in Virginia?
Is there an over-the-counter version of bremelanotide?
Is compounded PT-141 legal in Virginia?
Can a Virginia pharmacy fill a telehealth prescription for Vyleesi?
Does the Vyleesi label cover men?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is PT-141 legal?
Yes, with a prescription, for the FDA-approved product Vyleesi, which FDA approved on June 21, 2019 for premenopausal women with acquired, generalized HSDD. Compounded or research-use PT-141 is not Vyleesi and is not FDA-approved or reviewed by FDA for safety, effectiveness or quality.
Does PT-141 work for everyone?
Not established. Vyleesi is approved only for premenopausal women with acquired, generalized HSDD. The label says it is not indicated for HSDD in postmenopausal women or in men, or to enhance sexual performance, and it is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
When is the best time to inject PT-141?
The label says to inject 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. Do not give more than one dose within 24 hours, and more than 8 doses per month is not recommended.
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Code of Virginia Code - Chapter 34. Drug Control Act.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.